METHYLPREDNISOLONE
Clinical safety rating: avoid
Positive evidence of fetus risks but benefits may outweigh risks in some cases
Glucocorticoid receptor agonist; inhibits phospholipase A2, decreases prostaglandin and leukotriene synthesis; suppresses cytokine production and immune cell activity.
| Metabolism | Hepatic via CYP3A4; primarily metabolized to inactive metabolites. |
| Excretion | Renal (primarily as inactive metabolites, <10% unchanged); minor biliary/fecal elimination |
| Half-life | Plasma: 2.5-3.5 hours; biological half-life (tissue): 18-36 hours due to glucocorticoid receptor-mediated effects; clinical context: anti-inflammatory effects persist beyond plasma clearance |
| Protein binding | ~77% bound to albumin and corticosteroid-binding globulin (CBG); binding is concentration-dependent |
| Volume of Distribution | 0.8-1.3 L/kg; indicates extensive tissue distribution, including intracellular sites of action |
| Bioavailability | Oral: 70-90% (immediate-release); IM: ~100%; intra-articular: local, minimal systemic absorption |
| Onset of Action | IV: rapid (minutes); IM: 1-2 hours; oral: 1-2 hours; intra-articular: 6-12 hours; topical: variable, within days |
| Duration of Action | Single dose: 12-36 hours (biological effects); duration depends on dose, route, and condition; short-term use for acute inflammation; prolonged therapy for chronic conditions |
| Molecular Weight | 374.47 |
4-48 mg/day orally in divided doses; 10-40 mg IV/IM bolus, then 10-40 mg IV q4-6h; high-dose IV pulse: 1 g/day for 3 days.
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required for GFR >10 mL/min; for severe impairment (GFR <10 mL/min), use with caution and monitor for fluid retention. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B or C: initiate at lowest dose, titrate carefully due to increased risk of toxicity. |
| Pediatric use | 0.5-2 mg/kg/day orally in divided doses; IV: 0.5-1 mg/kg/dose q6-24h; pulse therapy: 30 mg/kg IV over 30 min daily for 3 days. |
| Geriatric use | Initiate at lowest effective dose; monitor for hyperglycemia, osteoporosis, immunosuppression; adjust for comorbidities and drug interactions. |
| 1st trimester | Corticosteroids are associated with a small increased risk of oral clefts. Use only if potential benefit justifies risk. |
| 2nd trimester | May use for maternal benefit; monitor fetal growth with prolonged use. |
| 3rd trimester | Prolonged use may cause neonatal adrenal suppression. Taper if used near term. |
Clinical note
CYP3A4 inducers (eg phenytoin) may decrease efficacy and inhibitors may increase effects Can cause hyperglycemia and adrenal suppression with prolonged use.
| Placental transfer | Crosses placenta; metabolized by placental 11β-HSD2 to less active prednisolone, but high doses can saturate the enzyme. |
| Breastfeeding | Methylprednisolone is excreted in breast milk in small amounts. Doses up to 40 mg daily are considered compatible with breastfeeding; however, high doses or prolonged use may require monitoring of the infant for adrenal suppression. |
■ FDA Black Box Warning
No FDA black box warning.
| Common Effects | immunosuppression |
| Serious Effects |
Systemic fungal infectionsHypersensitivity to methylprednisolone or any componentIntrathecal administration (contraindicated)
| Precautions | Adrenal suppression and insufficiency with prolonged use or rapid withdrawal, Increased risk of infections, Masking of infection signs, Gastrointestinal perforation (especially with NSAIDs), Osteoporosis with long-term use, Cataracts and glaucoma, Cushing's syndrome with high doses, Kaposi sarcoma reported |
| Food/Dietary | Avoid grapefruit and grapefruit juice as they may increase methylprednisolone levels. High-sodium foods should be limited due to fluid retention risk. Potassium-rich foods may be recommended if hypokalemia develops. |
Loading safety data…
| Lactation Rating | L2 - Safer |
| Teratogenic Risk | First trimester: Increased risk of cleft palate (odds ratio 3.35, 95% CI 1.97-5.69) with exposure. Second/third trimesters: Associated with fetal adrenal suppression, intrauterine growth restriction, and preterm birth. Chronic use may cause neonatal adrenal insufficiency. |
| Fetal Monitoring | Monitor maternal blood glucose, blood pressure, and signs of infection. Fetal ultrasound for growth restriction if used chronically. Newborn should be monitored for adrenal insufficiency (e.g., hypoglycemia, hypotension) if exposed in late pregnancy. |
| Fertility Effects | No known adverse effect on fertility. Chronic use may suppress hypothalamic-pituitary-adrenal axis but does not directly impair gametogenesis or reproductive function. |
| Clinical Pearls | Methylprednisolone is a potent corticosteroid with rapid onset; for acute asthma exacerbations, IV doses of 40-80 mg/day are typical; taper to avoid adrenal insufficiency; monitor for hyperglycemia, especially in diabetic patients; long-term use increases risk of osteoporosis, cataracts, and immunosuppression; consider Pneumocystis jirovecii prophylaxis if combined with other immunosuppressants; avoid live vaccines during therapy. |
| Patient Advice | Take with food or milk to reduce stomach upset. · Do not stop suddenly; dose must be tapered under medical supervision. · Report signs of infection (fever, sore throat), unusual bruising, or black/tarry stools. · Avoid live vaccines while on this medication. · Wear a medical alert bracelet if on long-term therapy. · Monitor blood glucose regularly if diabetic. |